Cardiovascular Outcome of Pediatric Patients With Bi-Allelic (Homozygous) Familial Hypercholesterolemia Before and After Initiation of Multimodal Lipid Lowering Therapy Including Lipoprotein Apheresis

Twenty-four patients with bi-allelic familial hypercholesterolemia (FH) commencing chronic lipoprotein apheresis (LA) at a mean age of 8.5 ± 3.1 years were analysed retrospectively and in part prospectively with a mean follow-up of 17.2 ± 5.6 years. Mean age at diagnosis was 6.3 ± 3.4 years. Untreated mean LDL-C concentrations were 752 mg/dl ± 193 mg/dl (19.5 mmol/l ± 5.0 mmol/l). Multimodal lipid lowering therapy (LLT) including LA resulted in a mean LDL-C concentration of 184 mg/dl [4.8 mmol/l], which represents a 75.5% mean reduction.

Source: The American Journal of Cardiology - September 14, 2020 Category: Cardiology Authors: Christina Taylan, Joenna Driemeyer, Claus P. Schmitt, Lars Pape, Rainer B üscher, Matthias Galiano, Jens König, Carsten Schürfeld, Ralf Spitthöver, Axel Versen, Michael Koziolek, Tobias A. Marsen, Holger Stein, Juergen R. Schaefer, Andreas Heibges, Re Source Type: research